Breakthrough targeted therapies—from KRAS and PROTACs to CAR T—plus ctDNA monitoring and personalized vaccines push earlier detection and smarter cancer treatment.
Feature|Articles|February 17, 2026
New 2026 ACS Data Show Cancer Survival Rates Hit a Historic 70%
Author(s)Sabrina Serani
Fact checked by: Georgina Carson, Andrea Eleazar, MHS
Cancer survival hits 70% as early screening and immunotherapy advance—yet survivorship needs and Indigenous disparities demand urgent action.
Advertisement
Advertisement
In the mid-1970s, a cancer diagnosis was essentially a coin toss, with a 5-year survival rate hovering at a grim 49%. Fast-forward to today, and that coin is now heavily weighted in favor of the patient. According to the American Cancer Society (ACS) report, Cancer Statistics, 2026, the medical community has reached a historic milestone: The 5-year relative survival rate for all cancers combined has officially hit 70%.
Related to this article
J. Thaddeus Beck, MD, discusses how the shift from intravenous to subcutaneous formulations is changing oncology practice, from clinic logistics to patient preferences.
Experts debate second-line tivozanib for advanced renal cell carcinoma, weighing PFS gains, tolerability, and whether continuing immunotherapy adds real benefit.
The designation expands the investigational immunotherapy’s development across tumor types for patients whose disease progresses after prior treatment, including immune checkpoint inhibition.
Phase 2b data show iopofosine I-131 drives deep, durable responses in relapsed Waldenström macroglobulinemia after BTK inhibitors, with manageable cytopenias.
The RELIGHT study found that adding retlirafusp alfa to chemotherapy extended overall and progression-free survival in previously untreated gastric and GEJ cancers.
Gary Simmons, DO, MSHA, discusses outpatient CAR T-cell therapy in the community, the operational and payer bottlenecks his practice has faced, and advice for colleagues.
During a virtual event, Neil M. Iyengar, MD, and participants discussed how approvals for trastuzumab deruxtecan before and after surgery complicate sequencing for patients with HER2-positive early breast cancer.
Advertisement
Advertisement